20 June 2022 | Statements

FIND, Unitaid and partners from the access to COVID-19 tools (ACT) Accelerator diagnostics pillar call on the G20 and G7 to prioritize diagnostics in its pandemic preparedness and response plans

The COVID-19 pandemic has shown that access to timely, accurate diagnostics is fundamental to effective healthcare. The Access to COVID-19 Tools (ACT) Accelerator is a unique but time-limited partnership that was set up to respond to the acute phase of the COVID-19 pandemic.

G7 and G20 countries, have so far pledged US$ 18.3 billion to the ACT-Accelerator, of which US$ 12.36 billion has been pledged to the vaccines pillar, COVAX. The G7 in its Health Ministers’ Communiqué (20 May 2022, Berlin) stated:

“We underline our support for all four pillars of the ACT-Accelerator, including its COVAX facility and recognize that supporting the ACT-Accelerator by all means, including with adequate funding, is central to end the acute pandemic.”

The ACT-Accelerator has played a critical role in delivery of diagnostics, therapeutics and vaccines. Investments by ACT-Accelerator partners will deliver benefits for global health programmes beyond COVID-19.

Testing and sequencing allow us to track disease evolution and spread, and facilitate access to treatments. As world leaders including the G7 and G20 are aligning efforts for future pandemic preparedness and creating a G7 Pact for Pandemic Readiness, FIND, Unitaid and ACT-Accelerator Diagnostics Pillar partners call on both G7 and G20 to reaffirm commitments relating to diagnostics as part of the 100 Days Mission put forward during the UK G7 Presidency in 2021:

Addressing shortfalls in diagnostic testing must be an urgent priority. Deficiencies in testing affect not only people’s lives, but communities and economies as well as our ability to ensure we can manage existing and future outbreaks of diseases, as COVID-19 showed clearly. Strong global leadership and political will is needed to accelerate change and lead the world towards a better future.

Media contact:

For more information and media requests:

Sarah Mascheroni

Communications officer

Email: mascheronisa@unitaid.who.int

Mobile: +41 79 728 73 11

View All News

Featured News

12 July 2024

Call for Expression of Interest (EOI): Strengthening sustainable regional manufacturing of therapeutics for Maternal health, Malaria and HIV programmatic priorities in Africa

Read More

09 July 2024

Unitaid and Jhpiego reach first women with prevention and treatment for life-threatening bleeding as program awarded EUR 5.5 million in additional funding

Read More

Sign Up for Unitaid Updates

  • This field is for validation purposes and should be left unchanged.